Anti-TNF (tumor necrosis factor) medications work by inhibiting the production of TNF or its effect on target organs. TNF is a cell-signaling protein, or cytokine, involved in systemic inflammation and is one of the cytokines that make up the acute phase reactants. TNF inhibitors are available for the treatment of a number of rheumatic and other immune-mediated diseases. Treatment of rheumatoid arthritis with anti-TNFα (tumor necrosis factor-alpha) agents may lead to autoantibody formation and flares of vasculitis. Although medications are a common cause of renal injury, anti-TNFα medications very rarely cause renal complications. We present a case of a patient who presented with nausea and flu-like illness and was ultimately found to have etanercept-induced nephropathy.
CITATION STYLE
Ammar, A., Zafar Ahmed Mahmood, H., Shahid, Z., Jain, R., & Chen, G. (2019). Etanercept-associated Nephropathy. Cureus. https://doi.org/10.7759/cureus.5419
Mendeley helps you to discover research relevant for your work.